DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/zw29tf/rhinoconjunctivit) has announced the addition of the “Rhino-Conjunctivitis-Pipeline Insights, 2016” report to their offering. Rhino-Conjunctivitis-Pipeline…
Category: Business
Inotek Pharmaceuticals to Present at Glaucoma 360 New Horizons Forum
LEXINGTON, Mass.–(BUSINESS WIRE)–Cadmus Rich, MD, Vice President, Medical Affairs and Clinical Development of Inotek, will present at Glaucoma 360: New Horizons Forum on Friday, January 29, 2016 at the Palace Hotel in San Francisco.
Recent Expansion of Columbia Eye Consultants Optometry Staff and Facilities Pave the Way for Additional Growth
COLUMBIA, Mo.–(BUSINESS WIRE)–Recent expansion of Columbia Eye Consultants Optometry staff and facilities pave the way for additional growth in 2016
The Levi’s® Brand Taps FGX International Inc. as its New Licensee Eyewear Partner
SMITHFIELD, R.I.–(BUSINESS WIRE)–FGX International, a leading eyewear designer and marketer, announced today they have teamed up with the Levi’s® brand to launch a unisex collection of branded Levi’s® eyewear for both sunglasses and optical frames. In the substantial and growing market of sunglasses and optical frames, the FGX International and Levi’s® collaboration will leverage FGX’s impressive 85 year heritage and market expertise of producing eyewear, and the long standing legacy of Levi
IDTechEx Research: Microdisplays enabling the AR-VR smartglasses revolution
BOSTON, Mass.–(BUSINESS WIRE)–If the buzz at CES is any indication of things to come (and it usually is), 2016 is expected to be the year of virtual reality (VR). Much anticipated VR headset launches, announcement of investment in enabling technologies, and developments of optimized components made virtual reality the words on everyone’s lips at the show. The new IDTechEx Research report “AR & VR Smartglasses and Functional Contact Lenses 2016-2026” discusses the market growth expected fo
PENTAX Europe GmbH acquisisce le azioni rimanenti di PENTAX Italia S.r.l. da Movi S.p.A.
Amburgo–(BUSINESS WIRE)–PENTAX Europe GmbH ha acquisito le azioni rimanenti di PENTAX Italia S.r.l. da Movi S.p.A. Quest’ulteriore investimento da parte di PENTAX Europe GmbH nel settore sanitario italiano rafforza la posizione di PENTAX Medical in Italia e contribuirà al miglioramento dei servizi e della formazione professionale da essa offerti ai propri clienti italiani. Fondata nel 2007, PENTAX Italia era comproprietà di PENTAX Europe GmbH e di Movi S.p.A., distributore italiano di prodott
Presbia PLC Appoints Gerald Farrell, Ph.D. to the Board of Directors
DUBLIN–(BUSINESS WIRE)–The Board of Directors of Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced today that it has appointed Gerald Farrell, Ph.D. to serve on its Board of Directors and as a member of its Audit Committee. Dr. Farrell has been involved in the pharmaceutical industry for more than 25 years, and worked for Eli Lilly Company Limited in Ireland and the United Kingdom for the majority of his successful career. Dr. Farrell’s
2020 On-site Optometry Announces New Board Member
BOSTON–(BUSINESS WIRE)–2020 On-site Optometry, a Boston-based healthcare startup focused on mobile eye care, is excited to announce that Mark J. Weikel has joined the company’s Board of Directors. Weikel brings expansive experience in the world of eyewear and retail. He served as President and CEO of Retail Optical North America for Luxottica, General Manager of LensCrafters and General Manager of Sunglass Hut North America. In addition, Weikel’s diverse retail experience includes influential
Kedrion Biopharma Expands Immunoglobulin Therapies Portfolio, Gains Commercial Rights in the U.S. to BIVIGAM®, a Recently Approved IGIV Brand
FORT LEE, N.J.–(BUSINESS WIRE)–Kedrion Biopharma Immunoglobulin portfolio has expanded to include four brands in the United States
Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Based on these results Eleven sees no immediate path forward in allergic conjunctivitis and will advance development of EBI-031 for diabetic macular edema with an IND filing in 1H2016.
Research and Markets: Global Optical Sensors Market Worth USD 20.94 Billion by 2020 – Analysis & Forecasts Report 2015-2020 – Key Vendors: Hitachi, SICK AG & Turck
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/kn9rzb/global_optical) has announced the addition of the “Global Optical Sensors Market By Sensor Type, Industry Usage Forecasts, Trends and Market Shares (2015- …
Glaukos Provides Preliminary Fourth Quarter and Full Year 2015 Net Sales and Full Year 2016 Net Sales Guidance
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
Renaissance Adds Dental Industry Veteran to Its Florida Sales Team
INDIANAPOLIS–(BUSINESS WIRE)–Renaissance, a leading ancillary insurance carrier of customizable dental and vision plans, is expanding its Florida office with the addition of dental-industry veteran Cynthia Byndas.
Inotek Pharmaceuticals Appoints Carsten Boess to Board of Directors
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek announces that Carsten Boess has been appointed to its Board of Directors and the Audit Committee of Inotek’s board.
EYE TECH CARE宣佈與中國投資者達成重要的注資和夥伴關係協定
法國里昂–(BUSINESS WIRE)–(美國商業資訊) — EYE TECH CARE SA是開發和行銷非侵入性青光眼治療眼科醫療器材的公司，該公司今天宣佈已獲得一家中國投資者的新一輪注資。恒松資本將分兩輪投資，總金額約為2500萬歐元，並將支持EYE TECH CARE的國際擴張。該公司將受益於恒松資本在中國大陸的佈局，從而推動已經於2015年啟動的產品報批。 中國大陸是該公司的主要市場：中國大陸有2200萬名青光眼患者，占全世界青光眼患者的28% (MarketScope 2014)。但由於治療水準相對較低，僅有6%左右的中國大陸患者獲得治療。多數青光眼患者屬於晚期，常需要使用複雜的治療手段。在此背景下，EYE TECH CARE開發的非侵入性治療可提供替代性解決方案，完美迎合中國大陸市場的需求。 這家法國公司開發的創新醫療器材EyeOP1®使用超音波來治療青光眼，為青光眼治療提供使用簡便的非侵入性解決方案。UCP手術（超音波睫狀體成形術）是唯一針對未獲控制的青光眼而開發的醫療手術，無論患者以往是否接受過治療。 EYE TECH CARE執行長Dietrich Wolf
EYE TECH CARE宣布与中国投资者达成一项重要的注资和伙伴关系协议
法国里昂–(BUSINESS WIRE)–(美国商业资讯) — EYE TECH CARE SA是一家开发和营销青光眼无创治疗眼科医疗器材的公司，该公司今天宣布已获得一家中国投资者的新一轮注资。恒松资本将分两轮投资，总金额约为2500万欧元，并将支持EYE TECH CARE的国际扩张。公司将受益于恒松资本在中国的布局，从而推进已经于2015年启动的产品报批。 中国是该公司的主要市场：中国有2200万青光眼患者，占世界青光眼患者的28% (MarketScope 2014)。但由于治疗水平相对较低，仅有6%左右的中国患者获得治疗。多数青光眼患者属于晚期，常需要使用复杂的治疗手段。在此背景下，EYE TECH CARE开发的无创治疗可提供替代性解决方案，完美符合中国市场的需求。 这家法国公司开发的创新医疗器材EyeOP1®为青光眼超声治疗提供了一个使用简便的无创解决方案。UCP手术（超声睫状体成形术）是唯一针对未获控制的青光眼而开发的医疗手术，无论患者既往是否接受过治疗。 EYE TECH CARE首席执行官Dietrich Wolf先生说：“我们很高兴地欢迎恒松资本成为公司的财
Bruker Presentation at the 34th Annual J.P. Morgan Healthcare Conference to be Webcast Live
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker (NASDAQ: BRKR) today announced that it will webcast its presentation to the investment community at the J.P. Morgan Healthcare Conference on Monday, January 11, 2016, at 1:30 p.m. Pacific Time. To listen to the live webcast, investors can go to http://ir.bruker.com and click on the “Events and Presentations” hyperlink to access the webcast. About Bruker Corporation For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries an
NovaBay Pharmaceuticals Secures $3 Million Bridge Loan
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova® Lid and Lash Cleanser for the domestic eye care market, announces that it has secured a $3 million bridge loan. NovaBay has already received approximately $1.66 million, with the remaining approximate $1.37 million to be funded later this month. The loan has a three-year term with no pre-payment penalty. The loan, managed by China Kington Asse
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today annou…
Ophthotech Announces Appointment of David E. Redlick to Its Board of Directors
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced the appointment of David E. Redlick to its Board of Directors effective immediately.